Literature DB >> 19879159

Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.

Abdoulreza Agheli Mansour1, Seyed Latif Mousavi, Iraj Rasooli, Shahram Nazarian, Jafar Amani, Nima Farhadi.   

Abstract

Botulinum neurotoxins (BoNTs) inhibit neurotransmitter release from peripheral cholinergic synapses. BoNTs consist of a toxifying light chain and a heavy chain (HC) linked through a disulfide bond. In the present study we explored the immunogenicity and protective capability of the most effective part corresponding to 1163-1256 residues of botulinum type E neurotoxin HC gene. DNA encoding the 93 C-terminal amino acid of HC residues was synthesized with optimal codon usage for expression. These DNA fragments were ligated into a pLivSelect vector and subcloned into expression vector pET32a. Recombinant plasmids were then transformed into Escherichia coli strain BL21 DE3. The recombinant protein was purified by nickel affinity gel column chromatography. The HC1163-1256 was identified by antibodies raised against BoNT/E. HC1163-1256 was shown to bind with synaptotagmin and gangliosides, indicating that the expressed and purified HC1163-1256 protein retains a functionally active conformation. The immunization with recombinant protein induced a protection level in mice. The immunization with 2mug of the recombinant protein induced a significant protection level in mice. In conclusion, availability of the recombinant protein provides an effective system to study the biochemical and physical interactions involved during BoNT binding to nerve cells and protection against its toxicity. (c) 2009 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879159     DOI: 10.1016/j.biologicals.2009.09.008

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  6 in total

1.  High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.

Authors:  Ebrahim Valipour; Mir-Latif Moosavi; Jafar Amani; Shahram Nazarian
Journal:  World J Microbiol Biotechnol       Date:  2014-01-29       Impact factor: 3.312

2.  Comparative study of immunological and structural properties of two recombinant vaccine candidates against botulinum neurotoxin type E.

Authors:  Mosayeb Rostamian; Seyed Jafar Mousavy; Firouz Ebrahimi; Seyyed Abolghasem Ghadami; Nader Sheibani; Mohammad Ebrahim Minaei; Mohammad Ali Arefpour Torabi
Journal:  Iran Biomed J       Date:  2012

3.  Immunogenicity evaluation of rBoNT/E nanovaccine after mucosal administration.

Authors:  Mohamad Javad Bagheripour; Firouz Ebrahimi; Abbas Hajizade; Shahram Nazarian
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

4.  Preparation of chitosan nanoparticle containing recombinant StxB antigen of EHEC and evaluation its immunogenicity in BALB/c mice.

Authors:  Pegah Almasian; Jafar Amani; Fahimeh Baghban Arani; Shahram Nazarian; Rouhollah Kazemi; Niloufar Mirzaee Tabrizi
Journal:  Iran J Microbiol       Date:  2018-12

5.  Evaluation of Crimean-Congo Hemorrhagic Fever Orthonairovirus AviTagged Nucleoprotein for Potential Application in Diagnosis

Authors:  Tahmineh Jalali; Mostafa Salehi-Vaziri; Mohammad Hassan Pouriayevali; Seyed Latif Mousavi Gargari
Journal:  Iran Biomed J       Date:  2019-05-20

6.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.